Opinion

$Emma Groarke on Ruxolitinib Study for Refractory T-LGL Leukemia from France$

Photo taken from onlinelibrary.wiley.com

Apr 26, 2024, 06:33

Emma Groarke on Ruxolitinib Study for Refractory T-LGL Leukemia from France

Emma Groarke, Hematologist at the National Institutes of Health (NIH), shared a post on X/Twitter:

“Nice paper from France in British Journal of Haematology on a series of relapsed/refractory T- Large granular lymphocytic leukemia (LGL) patients treated with Ruxolitinib.

Some response observed in 86% though complete response in 14%.

A potentially good option for patients going forward.”

$Emma Groarke on Ruxolitinib Study for Refractory T-LGL Leukemia from France$

Additional information.

British Journal of Haematology cancer Emma M. Groarke Large granular lymphocytic leukemia LGL National Institutes of Health NIH OncoDaily Oncology patients ruxolitinib T-LGL Leukemia

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage